{"id":801490,"date":"2025-01-16T07:35:59","date_gmt":"2025-01-16T12:35:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/"},"modified":"2025-01-16T07:35:59","modified_gmt":"2025-01-16T12:35:59","slug":"ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/","title":{"rendered":"Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200\u2014a Novel Integrin-Targeting Biologic for Diabetic Macular Edema"},"content":{"rendered":"
\n

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (\u201cOcugen\u201d or the \u201cCompany\u201d) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME).<\/p>\n

\u201cOCU200 has the potential to change the treatment landscape for DME, diabetic retinopathy (DR), and wet age-related macular degeneration (wet AMD) with its unique mechanism of action, binding the active component\u2014tumstatin\u2014to integrin receptors that play a crucial role in disease pathogenesis,\u201d said Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen. \u201cOCU200 holds the promise to benefit all DME patients, including the 30-40% of patients who do not respond to current anti-VEGF therapies.\u201d<\/p>\n

The OCU200 Phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal injection in three cohorts: low dose (0.025 mg), medium dose (0.05 mg), and high dose (0.1 mg). All subjects will receive a total of two intravitreal injections of OCU200 six weeks apart. Patient follow-up will take place up to three months after the last injection.<\/p>\n

Approximately 12 million people in the United States and 130 million people worldwide are affected by DME, DR or wet AMD. Patients affected by these diseases share common symptoms, such as blurriness in vision and progressive vision loss as the disease progresses. The formation of fragile and leaky new blood vessels leads to fluid accumulation in and around the retina, causing damage to vision.<\/p>\n

\u201cI am seeing an increasing rate of vision-threatening diseases associated with diabetes at my clinic and am eager to provide a new therapeutic option to these patients,\u201d said Dr. David Almedia, Vitreoretinal Surgeon and Clinician Scientist, President and CEO of Erie Retina Research, and Founder and President of Case X Global in Erie, Pennsylvania. \u201cThere remains a considerable unmet medical need for DME and DR patients with currently available anti-VEGF treatments.\u201d<\/p>\n

OCU200 is a recombinant fusion protein that consists of two parts connected by a linker: tumstatin, the active component, acts as an anti-inflammatory, anti-VEGF agent by binding to integrin receptors; and transferrin, which targets the drug to the choroid and retina by binding transferrin receptors on endothelial cells. These features will potentially enable OCU200 to reduce the vascular permeability, inflammation, and neovascularization that drive the pathophysiology of DME, DR, and wet AMD at a significantly lower dose compared to currently approved therapies.<\/p>\n

\u201cWe are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,\u201d said Dr. Huma Qamar, Chief Medical Officer at Ocugen. \u201cOCU200 brings an innovative biologic candidate to Ocugen\u2019s ophthalmology portfolio targeting blindness diseases.\u201d<\/p>\n

The Company intends to pursue approval to use OCU200 as a first-line therapy for DME, DR, and wet AMD.<\/p>\n

\n About Ocugen, Inc.<\/strong>
\n
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients\u2019 lives through courageous innovation\u2014forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at\u00a0www.ocugen.com<\/a>\u00a0and follow us on\u00a0X<\/a>\u00a0and\u00a0LinkedIn<\/a>.<\/p>\n

\n Cautionary Note on Forward-Looking Statements<\/strong>
\n
\n This<\/em>
\n press<\/em>
\n release<\/em>
\n contains<\/em>
\n forward-looking<\/em>
\n statements<\/em>
\n within<\/em>
\n the<\/em>
\n meaning<\/em>
\n of<\/em>
\n The<\/em>
\n Private<\/em>
\n Securities<\/em>
\n Litigation<\/em>
\n Reform<\/em>
\n Act<\/em>
\n of<\/em>
\n 1995,<\/em>
\n including,<\/em>
\n but<\/em>
\n not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines,<\/em>
\n which<\/em>
\n are<\/em>
\n subject<\/em>
\n to<\/em>
\n risks<\/em>
\n and<\/em>
\n uncertainties.<\/em>
\n We<\/em>
\n may,<\/em>
\n in<\/em>
\n some<\/em>
\n cases,<\/em>
\n use<\/em>
\n terms<\/em>
\n such<\/em>
\n as <\/em>
\n \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cproposed,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d <\/em>
\n or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including,<\/em>
\n but<\/em>
\n not<\/em>
\n limited<\/em>
\n to,<\/em>
\n the<\/em>
\n risks<\/em>
\n that<\/em>
\n preliminary,<\/em>
\n interim<\/em>
\n and<\/em>
\n top-line<\/em>
\n clinical<\/em>
\n trial<\/em>
\n results<\/em>
\n may<\/em>
\n not<\/em>
\n be<\/em>
\n indicative<\/em>
\n of,<\/em>
\n and<\/em>
\n may<\/em>
\n differ<\/em>
\n from,<\/em>
\n final<\/em>
\n clinical data;<\/em>
\n the ability of OCU200 to perform in humans in a manner consistent with nonclinical or preclinical study data;<\/em>
\n that<\/em>
\n unfavorable<\/em>
\n new<\/em>
\n clinical<\/em>
\n trial<\/em>
\n data<\/em>
\n may<\/em>
\n emerge<\/em>
\n in<\/em>
\n ongoing<\/em>
\n clinical<\/em>
\n trials<\/em>
\n or<\/em>
\n through<\/em>
\n further<\/em>
\n analyses<\/em>
\n of<\/em>
\n existing<\/em>
\n clinical<\/em>
\n trial<\/em>
\n data;<\/em>
\n that<\/em>
\n earlier non-clinical<\/em>
\n and<\/em>
\n clinical<\/em>
\n data<\/em>
\n and<\/em>
\n testing<\/em>
\n of<\/em>
\n may<\/em>
\n not<\/em>
\n be<\/em>
\n predictive<\/em>
\n of<\/em>
\n the<\/em>
\n results<\/em>
\n or<\/em>
\n success<\/em>
\n of<\/em>
\n later<\/em>
\n clinical<\/em>
\n trials;<\/em>
\n and<\/em>
\n that<\/em>
\n that<\/em>
\n clinical<\/em>
\n trial<\/em>
\n data<\/em>
\n are subject to differing interpretations and assessments, including by regulatory authorities.<\/em>
\n These<\/em>
\n and<\/em>
\n other<\/em>
\n risks<\/em>
\n and<\/em>
\n uncertainties<\/em>
\n are<\/em>
\n more<\/em>
\n fully described<\/em>
\n in<\/em>
\n our<\/em>
\n periodic<\/em>
\n filings<\/em>
\n with<\/em>
\n the<\/em>
\n Securities<\/em>
\n and<\/em>
\n Exchange<\/em>
\n Commission<\/em>
\n (SEC),<\/em>
\n including<\/em>
\n the<\/em>
\n risk<\/em>
\n factors<\/em>
\n described<\/em>
\n in<\/em>
\n the<\/em>
\n section<\/em>
\n entitled<\/em>
\n \u201cRisk Factors\u201d<\/em>
\n in<\/em>
\n the<\/em>
\n quarterly<\/em>
\n and<\/em>
\n annual<\/em>
\n reports<\/em>
\n that<\/em>
\n we<\/em>
\n file<\/em>
\n with<\/em>
\n the<\/em>
\n SEC.<\/em>
\n Any<\/em>
\n forward-looking<\/em>
\n statements<\/em>
\n that<\/em>
\n we<\/em>
\n make<\/em>
\n in<\/em>
\n this<\/em>
\n press<\/em>
\n release<\/em>
\n speak<\/em>
\n only<\/em>
\n as of<\/em>
\n the<\/em>
\n date<\/em>
\n of<\/em>
\n this<\/em>
\n press<\/em>
\n release.<\/em>
\n Except<\/em>
\n as<\/em>
\n required<\/em>
\n by<\/em>
\n law,<\/em>
\n we<\/em>
\n assume<\/em>
\n no<\/em>
\n obligation<\/em>
\n to<\/em>
\n update<\/em>
\n forward-looking<\/em>
\n statements<\/em>
\n contained<\/em>
\n in<\/em>
\n this<\/em>
\n press release whether as a result of new information, future events, or otherwise, after the date of this press release.<\/em>\n <\/p>\n

\n Contact:<\/strong>
\n
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (\u201cOcugen\u201d or the \u201cCompany\u201d) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). \u201cOCU200 has the potential to change the treatment landscape for DME, diabetic retinopathy (DR), and wet age-related macular degeneration (wet AMD) with its unique mechanism of action, binding the active component\u2014tumstatin\u2014to integrin receptors that play a crucial role in disease pathogenesis,\u201d said Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen. \u201cOCU200 holds the promise to benefit all DME patients, including the 30-40% of patients who … <\/p>\n

Continue reading “Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200\u2014a Novel Integrin-Targeting Biologic for Diabetic Macular Edema”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-801490","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOcugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200\u2014a Novel Integrin-Targeting Biologic for Diabetic Macular Edema - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200\u2014a Novel Integrin-Targeting Biologic for Diabetic Macular Edema - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (\u201cOcugen\u201d or the \u201cCompany\u201d) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). \u201cOCU200 has the potential to change the treatment landscape for DME, diabetic retinopathy (DR), and wet age-related macular degeneration (wet AMD) with its unique mechanism of action, binding the active component\u2014tumstatin\u2014to integrin receptors that play a crucial role in disease pathogenesis,\u201d said Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen. \u201cOCU200 holds the promise to benefit all DME patients, including the 30-40% of patients who … Continue reading "Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200\u2014a Novel Integrin-Targeting Biologic for Diabetic Macular Edema"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-16T12:35:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjkyMyM2Njk2OTI0IzIxODQ1MTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200\u2014a Novel Integrin-Targeting Biologic for Diabetic Macular Edema\",\"datePublished\":\"2025-01-16T12:35:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\\\/\"},\"wordCount\":930,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjkyMyM2Njk2OTI0IzIxODQ1MTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\\\/\",\"name\":\"Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200\u2014a Novel Integrin-Targeting Biologic for Diabetic Macular Edema - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjkyMyM2Njk2OTI0IzIxODQ1MTk=\",\"datePublished\":\"2025-01-16T12:35:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjkyMyM2Njk2OTI0IzIxODQ1MTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjkyMyM2Njk2OTI0IzIxODQ1MTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200\u2014a Novel Integrin-Targeting Biologic for Diabetic Macular Edema\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200\u2014a Novel Integrin-Targeting Biologic for Diabetic Macular Edema - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/","og_locale":"en_US","og_type":"article","og_title":"Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200\u2014a Novel Integrin-Targeting Biologic for Diabetic Macular Edema - Market Newsdesk","og_description":"MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (\u201cOcugen\u201d or the \u201cCompany\u201d) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). \u201cOCU200 has the potential to change the treatment landscape for DME, diabetic retinopathy (DR), and wet age-related macular degeneration (wet AMD) with its unique mechanism of action, binding the active component\u2014tumstatin\u2014to integrin receptors that play a crucial role in disease pathogenesis,\u201d said Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen. \u201cOCU200 holds the promise to benefit all DME patients, including the 30-40% of patients who … Continue reading \"Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200\u2014a Novel Integrin-Targeting Biologic for Diabetic Macular Edema\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-16T12:35:59+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjkyMyM2Njk2OTI0IzIxODQ1MTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200\u2014a Novel Integrin-Targeting Biologic for Diabetic Macular Edema","datePublished":"2025-01-16T12:35:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/"},"wordCount":930,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjkyMyM2Njk2OTI0IzIxODQ1MTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/","name":"Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200\u2014a Novel Integrin-Targeting Biologic for Diabetic Macular Edema - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjkyMyM2Njk2OTI0IzIxODQ1MTk=","datePublished":"2025-01-16T12:35:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjkyMyM2Njk2OTI0IzIxODQ1MTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjkyMyM2Njk2OTI0IzIxODQ1MTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ocu200-a-novel-integrin-targeting-biologic-for-diabetic-macular-edema\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200\u2014a Novel Integrin-Targeting Biologic for Diabetic Macular Edema"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/801490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=801490"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/801490\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=801490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=801490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=801490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}